Thesis (Ph. D.)--University of Wisconsin--Madison, 1969. / Typescript. Vita. Description based on print version record. Includes bibliographical references (leaves 294-317).

Thesis (M.D.) - University of St Andrews, November 2008. / Restricted until 12th November 2010.

Thesis (M.Sc.)(Biochemistry)--University of Pretoria, 2004. / Summaries in English and Afrikaans. Includes bibliographic references.

Thesis (M. Med. Sc.)--University of Hong Kong, 2005.

Humboldt-Universiẗat, Diss., 2001--Berlin.

Thesis (M.S.)--Indiana University, 2007. / Title from screen (viewed on Apr. 27, 2007) Department of Pharmacology & Toxicology, Indiana University-Purdue University Indianapolis (IUPUI) Includes vita. Includes bibliographical references (leaves 71-84)

No description available.

Master of Science in Biomedical Sciences / Department of Clinical Sciences / Elizabeth G. Davis / To protect horses from disease, equine practitioners typically prescribe a protocol of an initial primary vaccination followed by a booster vaccination 3-4 weeks later. Subsequent boosters are given every 6-12 months depending on the pathogen of concern. Each vaccination incurs an additional cost and increased chance for adverse reactions. Despite wide-spread protocol acceptance, duration of effectiveness of vaccines in protecting horses from disease is not well documented. It was hypothesized that horses vaccinated annually since birth have increased antibody production that remains consistent and sufficient for long-term protection from common diseases. This work resulted in the development of a novel, multiplex-magnetic bead-based indirect immunoassay to screen sera from vaccinated adult horses to measure antibody levels in response to vaccine administration. Antigens tested included West Nile Virus, Eastern Equine Encephalitis, Western Equine Encephalitis, Equine Influenza Virus, Equine Herpes Virus 1 and 4, Tetanus, and 7 different Rabies antigens (3 lab and 4 wild strains). The developed assay was a 7-plex capture antibody, which quantified equine IgG (Immunoglobulin G) that binds viral antigens derived from different rabies virus strains along with pure vaccine samples of the 7 different antigens. A 7-point standard curve was developed to quantify the viral-antigen reactive IgG concentration in vaccinated horse serum. Vaccinated horses increased serum antibody concentration for each antigen post-vaccination with the percent increase ranging between 34.0% for Equine Herpes Virus 4 and 257.3% for Equine Influenza Virus. Use of the novel assay will provide equine veterinarians with an economical method to measure immune activation toward common pathogens of concern. This methodology will provide foundation level information regarding antigen specific IgG concentrations that ultimately may be extrapolated to establish protective levels of immunity resulting in establishment of vaccine protocols.

Objective: The human immunodeficiency virus type 1 (HIV-1) currently infects over 30 million people worldwide. It uses one of two main co-receptors to infect cells. The primary objective of this thesis is to evaluate genotypic and phenotypic assays for co-receptor usage in the clinical setting and investigate approaches for improvement of these assays. Methods: The concordance of recombinant co-receptor phenotyping assays and the predictive ability of genotype-based methods including the ‘11/25’ rule, position specific scoring matrices (PSSMs), and support vector machines (SVMs) were evaluated in the clinical setting using patient-derived plasma samples. Samples and patient data were evaluated in cross-sectional analyses from a retrospective population-based cohort of HIV-infected individuals enrolled in the HIV/AIDS Drug Treatment Program in British Columbia, Canada. Results: Current implementations of HIV V3 region-based predictors for HIV co-receptor usage tested on patient derived samples are inadequate in the clinical setting, primarily due to low sensitivities as a result of difficult to detect minority species. Recombinant phenotype assays also show discordances when tested against each other on the same set of patient derived samples, raising doubts if any of these assays can truly be considered a ‘gold standard’. Significant associations between clinical progression, viral sequence-based predictors of co-receptor usage and the output of recombinant assays are observed, suggesting that sensitivity can be improved by incorporating CD4% into genotype-based predictors. This is verified with a SVM model which showed a 17% increase in sensitivity when CD4% was incorporated into training and testing. Conclusion: This work in this thesis has exposed the difficulty in determining the co-receptor phenotype in the clinical setting, primarily due to minority species. Although genotypic methods of screening for HIV co-receptor usage prior to the administration of CCR5 antagonists may reduce costs and increase turn-around time over phenotypic methods, they are currently inadequate for use in the clinical setting due to low sensitivities. Although the addition of clinical parameters such as CD4 count significantly increases the predictive ability of genotypic methods, the presence of low-levels of X4 virus continues to reduce the sensitivity of both genotypic and phenotypic methods. / Medicine, Faculty of / Medicine, Department of / Experimental Medicine, Division of / Graduate

The purpose of the present study was to compare the amounts of vitamin A in sweet potato flour with that of carrot flour and dehydrated carrots by using the biological assay method.